Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176), a urogenital cancer specialist, announced marketing approval from China’s National Medical Products Administration (NMPA) for Cevira, a photodynamic drug‑device combination product. The world’s first non‑surgical, non‑invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ‑preserving treatment.
World’s first non‑surgical, non‑invasive CIN2 therapy
Administration
Topical ointment + intravaginal cold light source
Phase III Clinical Evidence – Global Multi‑Center Study
Endpoint
Cevira Treatment Group
Placebo Group
Treatment Effect
Response Rate (CIN2)
49.6%
22.6%
+27 percentage points
Histopathological Regression (6 months)
57.5% regressed to normal/LSIL
30.6%
+26.9 percentage points
HPV Clearance (12 months)
~ 60% baseline HPV cleared
—
Significant viral elimination trend
Strategic Implications
Treatment Paradigm Disruption: Cevira eliminates need for surgical excision (LEEP, cone biopsy) in CIN2 patients—preserving cervical anatomy, reducing pregnancy complications, and eliminating surgical risks (bleeding, infection, cervical stenosis).
Global First‑in‑Class: As the world’s first approved non‑surgical CIN2 therapy, Cevira establishes Asieris as a pioneer in photodynamic gynecologic oncology, with licensing potential for US, EU, and emerging markets.
HPV Clearage Synergy: The ~ 60% HPV clearance rate suggests dual therapeutic benefit—lesion regression + viral elimination—potentially reducing cervical cancer risk beyond surgical excision, which does not address underlying HPV infection.
Device‑Drug Integration: The proprietary cold light source + photosensitizer ointment creates competitive moats through IP protection and manufacturing complexity, supporting premium pricing and market exclusivity.
Market Context
Factor
Impact
CIN2 Prevalence
~ 1‑2% of screened women globally; ~ 3‑5 million annual cases in China; current standard is surgical excision with significant overtreatment
Fertility Preservation
Surgical excision increases preterm birth risk; Cevira’s non‑invasive approach addresses unmet need in women of childbearing age
HPV Vaccine Complement
Cevira treats existing lesions in vaccinated/unvaccinated populations; potential for combination screening‑treatment programs
Asieris Pipeline Synergy
Cevira complements Asieris’s urogenital oncology portfolio (APL‑1202 for bladder cancer); establishes platform for photodynamic expansion into other HPV‑related diseases
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch timelines, reimbursement negotiations, and global partnership potential for Cevira. Actual results may differ due to risks including physician adoption curves, competitive loop electrosurgical excision procedure (LEEP) entrenchement, and long‑term recurrence data monitoring.-Fineline Info & Tech
By Fineline Cube 